SecBot SecBot

Ensuring Access to Lifesaving Drugs Act of 2023

H.R. 3793 Rep. Elissa Slotkin (D-MI-7) In committee
  1. Introduced Jun 5
  2. Committee Jun 5
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Jun 5, 2023Next: House vote
1237d ago Jun 9, 2023: Referred to the Subcommittee on Health.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
2companies, 2 filings
Member trades
5trades in the last 90 days
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

2 companies
Companies by sector
Financials 1Medical Devices & Healthcare 1
Search all 2 companies, their asks and price moves Subscribe

Summary

Ensuring Access to Lifesaving Drugs Act of 2023

Full summary2 paragraphs

This bill allows the Food and Drug Administration (FDA) to obtain additional information from manufacturers of life-saving drugs in order to assess and potentially modify the drug's expiration date. (The bill defines life-saving drug as a medical countermeasure or a drug that is in short supply and that is life-supporting, life-sustaining, or intended to be used to prevent or treat a debilitating disease or condition in humans or animals.)

Specifically, the FDA may order a manufacturer of a life-saving drug to submit data and other information from any stage of the drug's development in order to assess the drug's stability and the longest supported expiration date. If such information is not readily available, the FDA may order the manufacturer to conduct additional studies. The FDA may require changes to the drug's label accordingly. Manufacturers that fail to comply are subject to civil penalties.

Library of Congress summary, Jun 5, 2023

Summary versions
  • Introduced in HouseJun 5, 2023

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.